Fennec Pharmaceuticals: Is PEDMARK's Q1 2026 Performance a Game Changer

Related Articles

Is Chesapeake Utilities (CPK) Q1 2026 Performance a Game Changer for Investors

3 months ago

What Drove Neo Performance Materials' Record Q1 2026 Performance

3 months ago

What's Driving ARS Pharmaceuticals' Q1 2026 Earnings Narrative

3 months ago

What's Driving Regional Bank Performance in Q1 2026

3 months ago

Category

You may also like

Stock News•2 months ago

MannKind At An Inflection Point: Pediatric Expansion Drives The Story

MannKind received FDA approval to expand its Afrezza inhaled insulin therapy for pediatric patients aged 6 and older. The company targets a 360,000-patient U.S. base, projecting a $300M–$500M revenue ...

MNKD

Share

Stock News•2 months ago

Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside

Unicycive Therapeutics holds a $8/share valuation, split between $2/share in cash and $6/share for its pipeline. The company's lead candidate, OLC, targets hyperphosphatemia with a PDUFA date set for ...

UNCY

Share

Stock News•3 months ago

Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Fennec Pharmaceuticals reported Q1 2026 net revenues of $15.1 million, a 73% increase year-over-year. The growth follows a field sales expansion that drove record PEDMARK demand in April 2026, signali...

FENC

Share

Stock News•3 months ago

Merck: Bullish Setup Into Q1 Earnings

Merck & Co. is set to report Q1 earnings in late April. Investors are focused on the performance of Keytruda and Winrevair, alongside the strategic sales trajectory of Keytruda Qlex as a hedge against...

MRK

Share